Genetic analysis of large prostate cancer datasets has revealed that several co-activators of β-catenin-mediated transcriptional activity are amplified in prostate cancer, such as BCL9 and PYGO2 (Table 1) [64,65,66]. The gene discussed is PYGO2; the disease is prostate cancer.